---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093855"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:39:48.363838+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics Q2 net loss widens to $1.31/share; cash rises to $1.4B on $563M offering and $250M Royalty Pharma deal

## Summary
- Net loss of $143.3M ($1.31/share) vs $128.6M ($1.34/share) in Q2 2023; revenue down to $0.2M from $0.9M.
- Cash & investments $1.4B as of June 30, 2024, up from $634.3M at March 31, aided by $563.2M public offering and $250M upfront from Royalty Pharma.
- Rolling NDA for aficamten underway; Type B meeting with FDA held on risk mitigation; submission on track for Q3 2024.
- FDA cleared FOREST-HCM protocol amendment reducing echo monitoring frequency for obstructive HCM patients.
- Updated 2024 GAAP OpEx guidance raised to $555M-$575M (prev $535M-$555M); net cash use unchanged at $400M-$420M.

## SEC filing metadata
- accession: 0000950170-24-093855
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017024093855/0000950170-24-093855-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017024093855/cytk-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093855
- JSON: https://secwatch.observer/filing/0000950170-24-093855.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093855.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.